Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] stock went on an upward path that rose over 9.23% on Thursday, amounting to a one-week price increase of more than 13.73%.
Over the last 12 months, ARWR stock dropped by -35.13%. The one-year Arrowhead Pharmaceuticals Inc stock forecast points to a potential upside of 50.41. The average equity rating for ARWR stock is currently 1.71, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.68 billion, with 124.38 million shares outstanding and 115.84 million shares in the current float. Compared to the average trading volume of 1.53M shares, ARWR stock reached a trading volume of 3850570 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Arrowhead Pharmaceuticals Inc [ARWR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARWR shares is $43.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARWR stock is a recommendation set at 1.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Arrowhead Pharmaceuticals Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 05, 2024. While these analysts kept the previous recommendation, BofA Securities raised their target price to Buy. The new note on the price target was released on December 04, 2023, representing the official price target for Arrowhead Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $33, while Citigroup analysts kept a Neutral rating on ARWR stock.
The Average True Range (ATR) for Arrowhead Pharmaceuticals Inc is set at 1.14, with the Price to Sales ratio for ARWR stock in the period of the last 12 months amounting to 754.67. The Price to Book ratio for the last quarter was 14.44, with the Price to Cash per share for the same quarter was set at 5.47.
ARWR Stock Performance Analysis:
Arrowhead Pharmaceuticals Inc [ARWR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.73. With this latest performance, ARWR shares gained by 10.41% in over the last four-week period, additionally sinking by -25.19% over the last 6 months – not to mention a drop of -35.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARWR stock in for the last two-week period is set at 60.15, with the RSI for the last a single of trading hit 68.74, and the three-weeks RSI is set at 55.84 for Arrowhead Pharmaceuticals Inc [ARWR]. The present Moving Average for the last 50 days of trading for this stock 20.78, while it was recorded at 19.92 for the last single week of trading, and 22.84 for the last 200 days.
Insight into Arrowhead Pharmaceuticals Inc Fundamentals:
Arrowhead Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.74 and a Current Ratio set at 6.74.
Arrowhead Pharmaceuticals Inc [ARWR] Institutonal Ownership Details
There are presently around $79.71%, or 83.43%% of ARWR stock, in the hands of institutional investors. The top three institutional holders of ARWR stocks are: BLACKROCK INC. with ownership of 15.68 million shares, which is approximately 12.7211%. VANGUARD GROUP INC, holding 12.21 million shares of the stock with an approximate value of $$317.44 million in ARWR stocks shares; and VANGUARD GROUP INC, currently with $$231.02 million in ARWR stock with ownership which is approximately 7.21%.
